Ariana Pelosci

Miguel A. Materin, MD, discussed his new leadership role at Northwell Cancer Institute, and why a multidisciplinary approach is critical to managing ocular malignancies.

Nicholas Hornstein, MD, PhD, ranks RASolute 302, BREAKWATER, MATTERHORN, and more in a real-time discussion on Double Blind.

The FDA has accepted a BLA resubmission for RP1 plus nivolumab for patients with advanced melanoma.

Results from the phase 3 ASCENT-03 and ASCENT-04 trials supported the FDA approval across both locally advanced or metastatic TNBC indications.

Findings from the phase 3 PATINA trial support the FDA approval of palbociclib plus trastuzumab with or without pertuzumab in this breast cancer population.

Experts discussed the integration of GLP-1 agonists and lifestyle interventions to mitigate obesity-related cancer risks and improve long-term survival.

Based on data from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan/pembrolizumab for patients with clear cell RCC.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Patients with breast cancer experienced improvement in vasomotor symptoms when treated with elinzanetant, irrespective of type of endocrine therapy.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

In 897 patients with advanced melanoma treated with ICI, conditional 5-year PFS rose from 29% at baseline to 91% for those progression-free at 4 years.

Sacituzumab govitecan plus pembrolizumab maintained PFS improvements vs chemotherapy plus pembrolizumab in first-line metastatic TNBC.

An OS of 32.9 months was noted with RP1 plus nivolumab for patients who had progressed on prior anti-PD-1 therapy with advanced melanoma.

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

Patients with breast cancer who omitted sentinel lymph node surgery did not have an increased uptake in other forms of treatment like radiation therapy.

Data from the phase 3 VERITAC-2 trial support the FDA approval of vepdegestrant in this breast cancer population.

Post-surgical treatment, functional gains were improved among patients with breast cancer.

iSCIB1+ continues to be studied in the SCOPE trial for patients with advanced melanoma.

The 5-year OS rate was 16% and 8% in the tebentafusp and control arms, respectively, for patients with HLA-A*02:01–positive uveal melanoma.

The primary and secondary end points of the TANGENT trial were met when patients with tenosynovial giant cell tumor were treated with emactuzumab.

PFS showed statistically significant improvement with darovasertib plus crizotinib in the first line for patients with HLA-A*A2:01–negative metastatic uveal melanoma.

CT-P71 is being assessed in patients with locally advanced or metastatic urothelial carcinoma.

The FDA has set a Prescription Drug User Fee Act date of September 11, 2026, for TLX101-Px for patients with brain cancer.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI tool utilizes mammography to predict 5-year breast cancer risk.

A statistically significant pCR rate was noted in patients with HER2+ breast cancer treated with anbenitamab injection and albumin-bound docetaxel.

The incidence rates of breast cancer and colorectal cancer have been on the rise in patients under 50 years for the past several years.

The SkinJect data set found an overall response rate of approximately 80% for patients with nodular basal cell carcinoma receiving 200 µg of doxorubicin microneedle array.

Today the patient-physician relationship that Pergament et al outlined in 1999 is even more prevalent, driven by the rapid development, use, and uptake of social media across all oncology fronts.

Jesse Fann, MD, MPH, provided insights on the SCOPE trial, which evaluated technology-enhanced collaborative care for depression in patients undergoing active cancer treatment.